Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (331-340 of 353) with videos related to

Pageof 36
Sort By:
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
European Heart Journal|May 7, 2014
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled TrialA Michael Lincoff, Matthew Roe, Philip Aylward, et al.
American Heart Journal|December 6, 2021
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE studyShalender Bhasin, A Michael Lincoff, Shehzad Basaria, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialSophia Zoungas, David D'Alessio, Imre Pavo, et al.
JAMA|February 15, 2007
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trialGregg W Stone, Michel E Bertrand, Jeffrey W Moses, et al.
JAMA|November 15, 2020
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical TrialStephen J Nicholls, A Michael Lincoff, Michelle Garcia, et al.
Journal of the American College of Cardiology|September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II TrialC Michael Gibson, Gerald Chi, Danielle Duffy, et al.
The New England Journal of Medicine|June 16, 2023
Cardiovascular Safety of Testosterone-Replacement TherapyA Michael Lincoff, Shalender Bhasin, Panagiotis Flevaris, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Pageof 36

Showing results (331-340 of 353) with videos related to

Sort By:
Pageof 36
American Heart Journal|May 17, 2026
Cardiovascular Regulatory Science: Accelerating the Path from Bench to BedsideSerge Korjian, C Michael Gibson, Jonathan Seltzer, et al.
European Heart Journal|May 7, 2014
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled TrialA Michael Lincoff, Matthew Roe, Philip Aylward, et al.
American Heart Journal|December 6, 2021
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE studyShalender Bhasin, A Michael Lincoff, Shehzad Basaria, et al.
The New England Journal of Medicine|November 25, 2006
Bivalirudin for patients with acute coronary syndromesGregg W Stone, Brent T McLaurin, David A Cox, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialSophia Zoungas, David D'Alessio, Imre Pavo, et al.
JAMA|February 15, 2007
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trialGregg W Stone, Michel E Bertrand, Jeffrey W Moses, et al.
JAMA|November 15, 2020
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical TrialStephen J Nicholls, A Michael Lincoff, Michelle Garcia, et al.
Journal of the American College of Cardiology|September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II TrialC Michael Gibson, Gerald Chi, Danielle Duffy, et al.
The New England Journal of Medicine|June 16, 2023
Cardiovascular Safety of Testosterone-Replacement TherapyA Michael Lincoff, Shalender Bhasin, Panagiotis Flevaris, et al.
The New England Journal of Medicine|December 17, 2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesStephen J Nicholls, Imre Pavo, Deepak L Bhatt, et al.
Pageof 36